PI16 is expressed by a subset of human memory Treg with enhanced migration to CCL17 and CCL20

Ian C. Nicholson, Christos Mavrangelos, Daniel R G Bird, Suzanne Bresatz-Atkins, Nicola G. Eastaff-Leung, Randall H. Grose, Batjargal Gundsambuu, Danika Hill, Debbrah J. Millard, Timothy J. Sadlon, Sarah To, Heddy Zola, Simon C. Barry, Doreen Krumbiegel

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)


The peptidase inhibitor PI16 was shown previously by microarray analysis to be over-expressed by CD4-positive/CD25-positive Treg compared with CD4-positive/CD25-negative Th cells. Using a monoclonal antibody to the human PI16 protein, we found that PI16-positive Treg have a memory (CD45RO-positive) phenotype and express higher levels of FOXP3 than PI16-negative Treg. PI16-positive Treg are functional in suppressor assays . in vitro with potency similar to PI16-negative Treg. Further phenotyping of the PI16-positive Treg revealed that the chemokine receptors CCR4 and CCR6 are expressed by more of the PI16-positive/CD45RO-positive Treg compared with PI16-negative/CD45RO-positive Treg or Th cells. PI16-positive Treg showed enhanced . in vitro migration towards the inflammatory chemokines CCL17 and CCL20, suggesting they can migrate to sites of inflammation. We conclude that PI16 identifies a novel distinct subset of functional memory Treg which can migrate to sites of inflammation and regulate the pro-inflammatory response at those sites.

Original languageEnglish
Pages (from-to)12-18
Number of pages7
JournalCellular Immunology
Issue number1-2
Publication statusPublished or Issued - Jan 2012


  • Lymphocyte migration
  • Memory Treg
  • Peptidase inhibitor 16
  • Regulatory T cells

ASJC Scopus subject areas

  • Immunology

Cite this